Physician profile
Mark Uy Chan
NPI 1255569638
$667.79
in general payments reported to CMS, 2019-2025
15 companies · $21.44 in 2025
The $21.44 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $112 · 2021: $251 · 2025: $21.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $125.00 | 2021 | |
| Scilex Pharmaceuticals INC. | $72.01 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $65.18 | 2019-2021 | |
| Allergan, INC. | $59.92 | 2021 | |
| Pfizer INC. | $51.89 | 2019-2020 | |
| Radius Health, INC. | $46.24 | 2019 | |
| Collegium Pharmaceutical, INC. | $41.80 | 2019 | |
| Redhill Biopharma INC. | $39.35 | 2021 | |
| Bioventus LLC | $38.14 | 2019-2021 | |
| Pacira Therapeutics, INC. | $32.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $21.94 | 2019 | |
| Abbvie INC. | $21.44 | 2025 | |
| Assertio Therapeutics, INC. | $20.64 | 2020 | |
| Abbott Laboratories | $18.03 | 2019 | |
| Lilly USA, LLC | $13.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.